JP2018533589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533589A5 JP2018533589A5 JP2018522753A JP2018522753A JP2018533589A5 JP 2018533589 A5 JP2018533589 A5 JP 2018533589A5 JP 2018522753 A JP2018522753 A JP 2018522753A JP 2018522753 A JP2018522753 A JP 2018522753A JP 2018533589 A5 JP2018533589 A5 JP 2018533589A5
- Authority
- JP
- Japan
- Prior art keywords
- plasminogen
- subject
- drug
- days
- deficient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013566 Plasminogen Human genes 0.000 claims 86
- 108010051456 Plasminogen Proteins 0.000 claims 86
- 230000000694 effects Effects 0.000 claims 38
- 239000003814 drug Substances 0.000 claims 35
- 229940079593 drug Drugs 0.000 claims 28
- 230000002950 deficient Effects 0.000 claims 25
- 239000000126 substance Substances 0.000 claims 10
- 230000037396 body weight Effects 0.000 claims 8
- 230000007812 deficiency Effects 0.000 claims 6
- 230000003442 weekly effect Effects 0.000 claims 6
- 230000002354 daily effect Effects 0.000 claims 5
- 239000003146 anticoagulant agent Substances 0.000 claims 4
- 230000009469 supplementation Effects 0.000 claims 4
- 230000002537 thrombolytic effect Effects 0.000 claims 4
- 108700036309 Type I Plasminogen Deficiency Proteins 0.000 claims 3
- 208000007788 Acute Liver Failure Diseases 0.000 claims 2
- 206010000804 Acute hepatic failure Diseases 0.000 claims 2
- 208000007257 Budd-Chiari syndrome Diseases 0.000 claims 2
- 206010049811 Extraskeletal ossification Diseases 0.000 claims 2
- 208000034970 Heterotopic Ossification Diseases 0.000 claims 2
- 208000021798 Hypoplasminogenemia Diseases 0.000 claims 2
- 208000011200 Kawasaki disease Diseases 0.000 claims 2
- 208000020165 Neonatal respiratory disease Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000004276 hyalin Anatomy 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 208000013223 septicemia Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 206010071570 ligneous conjunctivitis Diseases 0.000 claims 1
- 230000001502 supplementing effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250235P | 2015-11-03 | 2015-11-03 | |
| US62/250,235 | 2015-11-03 | ||
| PCT/IB2016/001599 WO2017077380A1 (en) | 2015-11-03 | 2016-11-03 | Plasminogen replacement therapy for plasminogen-deficiency |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533589A JP2018533589A (ja) | 2018-11-15 |
| JP2018533589A5 true JP2018533589A5 (enExample) | 2019-12-12 |
| JP6878423B2 JP6878423B2 (ja) | 2021-05-26 |
Family
ID=58661917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522753A Active JP6878423B2 (ja) | 2015-11-03 | 2016-11-03 | プラスミノーゲン欠損症のためのプラスミノーゲン補充療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11291711B2 (enExample) |
| EP (1) | EP3370760B1 (enExample) |
| JP (1) | JP6878423B2 (enExample) |
| KR (1) | KR102821400B1 (enExample) |
| CN (1) | CN108289935A (enExample) |
| AU (1) | AU2016347863B2 (enExample) |
| BR (1) | BR112018008965A8 (enExample) |
| CA (1) | CA3002915C (enExample) |
| FI (1) | FI3370760T3 (enExample) |
| IL (1) | IL258913B (enExample) |
| MX (1) | MX2018005588A (enExample) |
| MY (1) | MY199581A (enExample) |
| RU (1) | RU2736831C2 (enExample) |
| TW (1) | TWI801331B (enExample) |
| WO (1) | WO2017077380A1 (enExample) |
| ZA (1) | ZA201802820B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201722464A (zh) * | 2015-11-10 | 2017-07-01 | 波麥堤克生化科學有限公司 | 用於傷口癒合之纖維蛋白溶酶原給藥方案 |
| DK3395359T5 (da) | 2015-12-18 | 2024-09-23 | Talengen Int Ltd | Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose |
| CA3008694C (en) | 2015-12-18 | 2022-11-29 | Talengen International Limited | Use of plasminogen for preventing or treating diabetic nerve injury and related disorders thereof |
| WO2017101871A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗心血管病的新方法 |
| JP6682008B2 (ja) | 2015-12-18 | 2020-04-15 | タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ | 糖尿病性腎症を予防及び治療するための方法 |
| EP3429636A4 (en) * | 2016-03-17 | 2019-11-20 | Vanderbilt University | IMPROVEMENT OF PLASMINACTIVITY FOR PREVENTING SOFT TISSUE CALIBRATION |
| TWI677348B (zh) | 2016-12-15 | 2019-11-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種改善心臟病變的方法 |
| TW201829448A (zh) | 2016-12-15 | 2018-08-16 | 大陸商深圳瑞健生命科學硏究院有限公司 | 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途 |
| US20190314466A1 (en) | 2016-12-15 | 2019-10-17 | Talengen International Limited | Method for preventing and treating skin fibrosis |
| US20190328850A1 (en) * | 2016-12-15 | 2019-10-31 | Talengen International Limited | Method for preventing and treating lipid metabolism disorders and related diseases thereof |
| EP3556390B1 (en) * | 2016-12-15 | 2024-04-03 | Talengen International Limited | Plasminogen for use in treating diabetes |
| CN109125715A (zh) * | 2017-06-19 | 2019-01-04 | 深圳瑞健生命科学研究院有限公司 | 一种调控glp-1/glp-1r的方法和药物 |
| TWI714862B (zh) | 2017-06-19 | 2021-01-01 | 大陸商深圳瑞健生命科學硏究院有限公司 | 一種調控glp-1/glp-1r的方法和藥物 |
| TWI868051B (zh) | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| US20220072110A1 (en) * | 2019-01-24 | 2022-03-10 | Previpharma Consulting Gmbh | Plasminogen for treating and preventing microthrombosis |
| EP3812772B1 (en) * | 2019-10-24 | 2025-02-19 | Hôpitaux Universitaires de Strasbourg (HUS) | Method for diagnosing fibrinolytic insufficiency related to neutrophil extracellular traps |
| WO2021214320A1 (en) | 2020-04-23 | 2021-10-28 | Previpharma Consulting Gmbh | Plasminogen for use in treating and preventing lung dysfunction |
| CN114354929A (zh) * | 2022-01-07 | 2022-04-15 | 南京鼓楼医院 | 一种用于监测人体纤溶状态的试剂盒及应用 |
| WO2025049724A1 (en) * | 2023-08-29 | 2025-03-06 | Board Of Regents Of The University Of Nebraska | Compositions and methods for treating pleural space infections and hemothorax |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2254316B1 (enExample) | 1973-12-18 | 1977-04-22 | Choay Sa | |
| JP2764264B2 (ja) * | 1987-10-01 | 1998-06-11 | 株式会社ミドリ十字 | 線溶活性増強剤 |
| AT402367B (de) * | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
| WO1994001128A1 (en) * | 1992-07-01 | 1994-01-20 | Beth Israel Hospital Boston | Enhancement of thrombolytic therapy with deglycosylated plasminogen |
| WO1994018315A1 (en) * | 1993-02-05 | 1994-08-18 | Vascular Laboratories, Inc. | Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis |
| US20030224516A1 (en) * | 2002-06-03 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of prox-1 expression |
| US7067492B2 (en) * | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| US20050271636A1 (en) * | 2002-08-09 | 2005-12-08 | St. Jude Children's Research Hospital, Inc. | Diagnostic and therapeutic uses for prox 1 |
| GB0509438D0 (en) * | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
| ES2453496T3 (es) | 2006-08-28 | 2014-04-08 | Omnio Healer Ab | Diana farmacológica novedosa de prevención y tratamiento de enfermedad periodontal, mejora de la cicatrización de heridas periodontales y promoción de la salud oral |
| MX2009002226A (es) * | 2006-08-28 | 2009-09-07 | Omnio Healer Ab | Candidatos contra infeccion. |
| AU2010270146B9 (en) * | 2009-07-10 | 2015-04-02 | Thrombogenics Nv | Variants of plasminogen and plasmin |
| RU2013112654A (ru) * | 2010-08-30 | 2014-10-10 | Президент Энд Феллоуз Ов Харвард Колледж | Высвобождение, контролируемое сдвигом, для повреждений, вызванных стенозом, и тромболитических терапий |
| KR102692851B1 (ko) | 2014-12-19 | 2024-08-06 | 프로메틱 바이오 테라퓨틱스 인코포레이티드 | 플라스미노겐을 포함하는 약학 조성물 및 이의 용도 |
| US10709771B2 (en) * | 2015-12-18 | 2020-07-14 | Talengen International Limited | Method for preventing or treating diabetic retinopathy |
-
2016
- 2016-11-02 TW TW105135535A patent/TWI801331B/zh active
- 2016-11-03 US US15/771,454 patent/US11291711B2/en active Active
- 2016-11-03 FI FIEP16861682.9T patent/FI3370760T3/fi active
- 2016-11-03 CA CA3002915A patent/CA3002915C/en active Active
- 2016-11-03 WO PCT/IB2016/001599 patent/WO2017077380A1/en not_active Ceased
- 2016-11-03 RU RU2018120182A patent/RU2736831C2/ru active
- 2016-11-03 JP JP2018522753A patent/JP6878423B2/ja active Active
- 2016-11-03 EP EP16861682.9A patent/EP3370760B1/en active Active
- 2016-11-03 MX MX2018005588A patent/MX2018005588A/es unknown
- 2016-11-03 AU AU2016347863A patent/AU2016347863B2/en active Active
- 2016-11-03 CN CN201680067482.XA patent/CN108289935A/zh active Pending
- 2016-11-03 KR KR1020187015657A patent/KR102821400B1/ko active Active
- 2016-11-03 BR BR112018008965A patent/BR112018008965A8/pt not_active Application Discontinuation
- 2016-11-03 MY MYPI2018000585A patent/MY199581A/en unknown
-
2018
- 2018-04-24 IL IL258913A patent/IL258913B/en unknown
- 2018-04-26 ZA ZA2018/02820A patent/ZA201802820B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533589A5 (enExample) | ||
| RU2018120182A (ru) | Плазминоген-заместительная терапия при дефиците плазминогена | |
| EP2635269B1 (en) | A combination composition | |
| JP2020033360A5 (enExample) | ||
| Kelly et al. | Beta-adrenergic agonists for acute, severe asthma | |
| Kumar et al. | The syndrome of irreversible acidosis after prolonged propofol infusion | |
| Khilnani et al. | Non-invasive ventilation after extubation in patients with chronic obstructive airways disease: a randomised controlled trial | |
| ES2971959T3 (es) | Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2013541583A5 (enExample) | ||
| King et al. | Bradycardia in a pediatric heart transplant recipient: is it the sugammadex? | |
| JP2018531605A5 (enExample) | ||
| AU2011274652B2 (en) | A combination composition comprising ibuprofen and paracetamol | |
| JP2020531568A5 (enExample) | ||
| JP2016510040A5 (enExample) | ||
| Fabi et al. | Are nasal decongestants safer than rhinitis? A case of oxymetazoline-induced syncope | |
| Yaman et al. | Neuroleptic malignant syndrome associated with metoclopramide in a child | |
| Akca et al. | Nebulized epinephrine treatment in pediatric emergency department | |
| Walsh et al. | A pediatric case study of treprostinil overdose | |
| EP3906934A1 (en) | Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections | |
| Graff et al. | Chloroquine Ingestion to Prevent SARS-CoV-2 Infection: A Report of Two Cases | |
| Iskit et al. | Pediatric Asthma Management | |
| Hwang et al. | Serotonin Syndrome Induced by Drug Interaction of Isoniazid and Metoclopramide | |
| Haitsma et al. | Surfactant Therapy | |
| Nagaraj | NEUROLEPTIC MALIGNANT SYNDROME IN A CHILD WITH ORGANOPHOSPHORUS POISONING |